Show simple item record

dc.contributor.authorBhuller, Kaljit
dc.date.accessioned2022-03-15T12:46:19Z
dc.date.available2022-03-15T12:46:19Z
dc.date.issued2022
dc.identifier.citationFollows, G. A., Barrington, S. F., Bhuller, K. S., Culligan, D. J., Cutter, D. J., Gallop-Evans, E., Kassam, S., Osborne, W., Sadullah, S., Townsend, W., Uttenthal, B. J., Collins, G. P., & British Society for Haematology (2022). Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline. British journal of haematology, 10.1111/bjh.18083. Advance online publication. https://doi.org/10.1111/bjh.18083en_US
dc.identifier.other10.1111/bjh.18083
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15254
dc.description.abstractThis guideline was compiled according to the British Society for Haematology (BSH) process at BSH Guidelines Process 2016 (b-s-h.org.uk). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Recommendations are based on a review of the literature using Medline, PubMed/Medline and Cochrane searches beginning from 2013 up to January 2021. The following search terms were used: [Hodgkin lymphoma OR Hodgkin disease] NOT non-Hodgkin; AND [chemotherapy OR radiotherapy]; AND [elderly]; AND [teenage OR adolescent OR young adult]; AND [pregnancy]. Filters were applied to include only publications written in English, studies carried out in humans, clinical conferences, congresses, clinical trials, clinical studies, meta-analyses, multicentre studies and randomised controlled trials. References pre-2013 were taken from the previous version of this guideline.1 Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Committee Haematology Oncology Taskforce, the BSH Guidelines Committee and the Haematology Oncology sounding board of BSH.
dc.description.urihttps://onlinelibrary.wiley.com/doi/10.1111/bjh.18083en_US
dc.subjectHodgkin's lymphomaen_US
dc.subjectchemotherapy;en_US
dc.subjectradiotherapyen_US
dc.subjectguidelineen_US
dc.titleGuideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guidelineen_US
dc.typeOtheren_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1111/bjh.18083en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
html.description.abstractThis guideline was compiled according to the British Society for Haematology (BSH) process at BSH Guidelines Process 2016 (b-s-h.org.uk). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Recommendations are based on a review of the literature using Medline, PubMed/Medline and Cochrane searches beginning from 2013 up to January 2021. The following search terms were used: [Hodgkin lymphoma OR Hodgkin disease] NOT non-Hodgkin; AND [chemotherapy OR radiotherapy]; AND [elderly]; AND [teenage OR adolescent OR young adult]; AND [pregnancy]. Filters were applied to include only publications written in English, studies carried out in humans, clinical conferences, congresses, clinical trials, clinical studies, meta-analyses, multicentre studies and randomised controlled trials. References pre-2013 were taken from the previous version of this guideline.1 Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Committee Haematology Oncology Taskforce, the BSH Guidelines Committee and the Haematology Oncology sounding board of BSH.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record